SCHEMBL3407486

SCHEMBL3407486

Cc1cc(N2CCS(=O)(=O)CC2)nc(Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.44
CRHBP P24387 2/20 0.41
CRHR2 Q13324 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KMT2A Q03164 2/20 0.41
NPSR1 Q6W5P4 1/20 0.39
CNR2 P34972 1/20 0.38
GBA1 P04062 3/20 0.38
KCNH2 Q12809 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
MAPT P10636 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GFER P55789 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9884923 0.81 HRH4 (0.64) HRH4KMT2ANPSR1KDM4EHSD17B10
SCHEMBL3405363 0.81 CRHBP (0.61) HRH4CRHBPCRHR2SMN1; SMN2KMT2A
SCHEMBL3410886 0.80 CRHBP (0.64) HRH4CRHBPCRHR2SMN1; SMN2KMT2A
SCHEMBL3406616 0.77 KDM4E (0.44) HRH4CRHBPCRHR2SMN1; SMN2KMT2A
SCHEMBL2531188 0.77 KMT2A (0.68) HRH4CRHBPCRHR2SMN1; SMN2KMT2A
SCHEMBL20043262 0.77 CASP1 (0.50) HRH4CRHBPCRHR2SMN1; SMN2KMT2A
SCHEMBL21193554 0.75 GBA1 (0.66) GBA1MAPT
SCHEMBL18153393 0.75 GBA1 (0.51) HRH4GBA1LMNA
SCHEMBL31646970 0.74 HRH4 (0.44) HRH4CRHBPCRHR2SMN1; SMN2KMT2A
SCHEMBL3408829 0.74 KCNH2 (0.45) HRH4CRHBPCRHR2SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962834-B2 Modulators of amyloid beta HOFFMANN-LA ROCHE INC. (US) 2015-02-24 US disclosed
EP-2257541-B1 MODULATORS FOR AMYLOID BETA HOFFMANN LA ROCHE (CH) 2013-08-14 EP disclosed
US-20130190302-A1 MODULATORS OF AMYLOID BETA HOFFMANN-LA ROCHE INC. (US) 2013-07-25 US disclosed
EP-2257541-A1 MODULATORS FOR AMYLOID BETA F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
US-20090215759-A1 MODULATORS FOR AMYLOID BETA HOFFMANN-LA ROCHE, INC. 2009-08-27 US disclosed
WO-2009103652-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215759-A1 MODULATORS FOR AMYLOID BETA APP, PSEN1, APOB HRH4 2013/4885CRHBP 1631/4885CRHR2 4227/4885
US-20130190302-A1 MODULATORS OF AMYLOID BETA APP, PSEN1, APOB HRH4 2204/4885CRHBP 1701/4885CRHR2 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.